Abstract
Introduction: Although urothelial papilloma (UP) is an indolent papillary neoplasm that can mimic the morphology of low-grade papillary urothelial carcinoma (PUC), there is no immunomarker to differentiate reliably these two entities. In addition, the molecular characteristics of UP are not fully understood. Methods: We conducted an in-depth proteomic analysis of papillary urothelial lesions (n = 31), including UP and PUC along with normal urothelium. Protein markers distinguishing UP and PUC were selected with machine learning analysis, followed by internal and external validation using immunohistochemistry. Results: In the proteomic analysis, UP and PUC showed overlapping proteomic profiles. We identified EHD4 and KRT18 as candidate diagnostic biomarkers of UP. Through immunohistochemical validation in two independent cohorts (n = 120), KRT18 was suggested as a novel UP diagnostic marker, able to differentiate UP from low-grade PUC. We also found that 3.5% of patients with UP developed urothelial carcinoma in subsequent resections, supporting the malignant potential of UP. KRT18 downregulation was significantly associated with UPs subsequently progressing to urothelial carcinoma, following their initial diagnosis. Conclusion: This is the first study that successfully revealed UPs comprehensive proteomic landscape, while it also identified KRT18 as a potential diagnostic biomarker of UP.
Journal Section:
Research Article
References
1.
Samaratunga
H
, Martignoni
G
, Egevad
L
, Delahunt
B
. Premalignant lesions of the urinary bladder
. Pathology
. 2013
;45
(3
):243
–50
. 2.
McKenney
JK
, Amin
MB
, Young
RH
. Urothelial (transitional cell) papilloma of the urinary bladder: a clinicopathologic study of 26 cases
. Mod Pathol
. 2003
;16
(7
):623
–9
. 3.
van Rhijn
BW
, Montironi
R
, Zwarthoff
EC
, Jobsis
AC
, van der Kwast
TH
. Frequent FGFR3 mutations in urothelial papilloma
. J Pathol
. 2002
;198
(2
):245
–51
. 4.
Isharwal
S
, Hu
W
, Sarungbam
J
, Chen
YB
, Gopalan
A
, Fine
SW
, et al. Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladder
. J Pathol
. 2019
;248
(3
):260
–5
. 5.
Cheng
L
, Montironi
R
, Lopez-Beltran
A
. TERT promoter mutations occur frequently in urothelial papilloma and papillary urothelial neoplasm of low malignant potential
. Eur Urol
. 2017
;71
(3
):497
–8
. 6.
Al Bashir
S
, Yilmaz
A
, Gotto
G
, Trpkov
K
. Long term outcome of primary urothelial papilloma: a single institution cohort
. Pathology
. 2014
;46
(1
):37
–40
. 7.
Magi-Galluzzi
C
, Epstein
JI
. Urothelial papilloma of the bladder: a review of 34 de novo cases
. Am J Surg Pathol
. 2004
;28
(12
):1615
–20
. 8.
Lee
JH
, Kim
YW
, Chang
SG
. Glucose transporter-1 expression in urothelial papilloma of the bladder
. Urol Int
. 2005
;74
(3
):268
–71
. 9.
Cheng
L
, Darson
M
, Cheville
JC
, Neumann
RM
, Zincke
H
, Nehra
A
, et al. Urothelial papilloma of the bladder. Clinical and biologic implications
. Cancer
. 1999
;86
(10
):2098
–101
. 10.
Harel
M
, Ortenberg
R
, Varanasi
SK
, Mangalhara
KC
, Mardamshina
M
, Markovits
E
, et al. Proteomics of melanoma response to immunotherapy reveals mitochondrial dependence
. Cell
. 2019
;179
(1
):236
–50.e18
. 11.
Tyanova
S
, Albrechtsen
R
, Kronqvist
P
, Cox
J
, Mann
M
, Geiger
T
. Proteomic maps of breast cancer subtypes
. Nat Commun
. 2016
;7
:10259
. 12.
Jung
M
, Lee
C
, Han
D
, Kim
K
, Yang
S
, Nikas
IP
, et al. Proteomic-based machine learning analysis reveals PYGB as a novel immunohistochemical biomarker to distinguish inverted urothelial papilloma from low-grade papillary urothelial carcinoma with inverted growth
. Front Oncol
. 2022
;12
:841398
. 13.
Lee
H
, Kim
K
, Woo
J
, Park
J
, Kim
H
, Lee
KE
, et al. Quantitative proteomic analysis identifies AHNAK (Neuroblast Differentiation-associated Protein AHNAK) as a novel candidate biomarker for bladder urothelial carcinoma diagnosis by liquid-based cytology
. Mol Cell Proteomics
. 2018
;17
(9
):1788
–802
. 14.
Park
JH
, Lee
C
, Han
D
, Lee
JS
, Lee
KM
, Song
MJ
, et al. Moesin (MSN) as a novel proteome-based diagnostic marker for early detection of invasive bladder urothelial carcinoma in liquid-based cytology
. Cancers
. 2020
;12
(4
):1018
. 15.
Netto
GJ
, Amin
MB
, Berney
DM
, Comperat
EM
, Gill
AJ
, Hartmann
A
, et al. The 2022 World Health Organization classification of tumors of the urinary system and male genital organs-part B: prostate and urinary tract tumors
. Eur Urol
. 2022
;82
(5
):469
–82
. 16.
Wichmann
C
, Meier
F
, Virreira Winter
S
, Brunner
AD
, Cox
J
, Mann
M
. MaxQuant.Live enables global targeting of more than 25,000 peptides
. Mol Cell Proteomics
. 2019
;18
(5
):982
–94
. 17.
Cox
J
, Neuhauser
N
, Michalski
A
, Scheltema
RA
, Olsen
JV
, Mann
M
. Andromeda: a peptide search engine integrated into the maxquant environment
. J Proteome Res
. 2011
;10
(4
):1794
–805
. 18.
Tyanova
S
, Temu
T
, Cox
J
. The maxquant computational platform for mass spectrometry-based shotgun proteomics
. Nat Protoc
. 2016
;11
(12
):2301
–19
. 19.
Schwanhausser
B
, Busse
D
, Li
N
, Dittmar
G
, Schuchhardt
J
, Wolf
J
, et al. Global quantification of mammalian gene expression control
. Nature
. 2011
;473
(7347
):337
–42
. 20.
Tyanova
S
, Temu
T
, Sinitcyn
P
, Carlson
A
, Hein
MY
, Geiger
T
, et al. The Perseus computational platform for comprehensive analysis of (prote)omics data
. Nat Methods
. 2016
;13
(9
):731
–40
. 21.
Kim
B
, Jung
M
, Moon
KC
, Han
D
, Kim
K
, Kim
H
, et al. Quantitative proteomics identifies TUBB6 as a biomarker of muscle-invasion and poor prognosis in bladder cancer
. Int J Cancer
. 2023
;152
(2
):320
–30
. 22.
Kim
JY
, Han
D
, Kim
H
, Jung
M
, Ryu
HS
. The proteomic landscape shows oncologic relevance in cystitis glandularis
. J Pathol Transl Med
. 2023
;57
(1
):67
–74
. 23.
Robertson
AG
, Kim
J
, Al-Ahmadie
H
, Bellmunt
J
, Guo
G
, Cherniack
AD
, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer
. Cell
. 2017
;171
(3
):540
–56.e25
. 24.
Szklarczyk
D
, Gable
AL
, Lyon
D
, Junge
A
, Wyder
S
, Huerta-Cepas
J
, et al. String v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets
. Nucleic Acids Res
. 2019
;47
(D1
):D607
–13
. 25.
Shannon
P
, Markiel
A
, Ozier
O
, Baliga
NS
, Wang
JT
, Ramage
D
, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks
. Genome Res
. 2003
;13
(11
):2498
–504
. 26.
Liang
Z
, Chen
Y
, Wang
L
, Li
D
, Yang
X
, Ma
G
, et al. CYP27A1 inhibits bladder cancer cells proliferation by regulating cholesterol homeostasis
. Cell Cycle
. 2019
;18
(1
):34
–45
. 27.
Catto
JW
, Abbod
MF
, Wild
PJ
, Linkens
DA
, Pilarsky
C
, Rehman
I
, et al. The application of artificial intelligence to microarray data: identification of a novel gene signature to identify bladder cancer progression
. Eur Urol
. 2010
;57
(3
):398
–406
. 28.
Li
YP
, Jia
XP
, Jiang
YQ
, Wang
W
, Wang
YL
, Wang
XL
, et al. Differential expression of cytokeratin 14 and 18 in bladder cancer tumorigenesis
. Exp Biol Med
. 2018
;243
(4
):344
–9
. 29.
Benedict
WF
, Fisher
M
, Zhang
XQ
, Yang
Z
, Munsell
MF
, Dinney
CN
. Use of monitoring levels of soluble forms of cytokeratin 18 in the urine of patients with superficial bladder cancer following intravesical Ad-IFNα/Syn3 treatment in a phase l study
. Cancer Gene Ther
. 2014
;21
(3
):91
–4
. 30.
Chen
Z
, Zhang
F
, Zhang
S
, Ma
L
. The down-regulation of SNCG inhibits the proliferation and invasiveness of human bladder cancer cell line 5637 and suppresses the expression of MMP-2/9
. Int J Clin Exp Pathol
. 2020
;13
(7
):1873
–9
.31.
Matsumoto
M
, Kawakami
K
, Enokida
H
, Toki
K
, Matsuda
R
, Chiyomaru
T
, et al. CpG hypermethylation of human four-and-a-half LIM domains 1 contributes to migration and invasion activity of human bladder cancer
. Int J Mol Med
. 2010
;26
(2
):241
–7
. 32.
Roperto
S
, Russo
V
, Esposito
I
, Ceccarelli
DM
, Paciello
O
, Avallone
L
, et al. Mincle, an innate immune receptor, is expressed in urothelial cancer cells of papillomavirus-associated urothelial tumors of cattle
. PLoS One
. 2015
;10
(10
):e0141624
. 33.
Steen
K
, Chen
D
, Wang
F
, Majumdar
R
, Chen
S
, Kumar
S
, et al. A role for keratins in supporting mitochondrial Organization and function in skin keratinocytes
. Mol Biol Cell
. 2020
;31
(11
):1103
–11
. 34.
Jung
M
, Lee
JH
, Kim
B
, Park
JH
, Moon
KC
. Transcriptional analysis of immunohistochemically defined subgroups of non-muscle-invasive papillary high-grade upper tract urothelial carcinoma
. Int J Mol Sci
. 2019
;20
(3
):570
. 35.
Jung
M
, Kim
B
, Moon
KC
. Immunohistochemistry of cytokeratin (CK) 5/6, CD44 and CK20 as prognostic biomarkers of non-muscle-invasive papillary upper tract urothelial carcinoma
. Histopathology
. 2019
;74
(3
):483
–93
. 36.
Jung
M
, Jang
I
, Kim
K
, Moon
KC
. Non-muscle-invasive bladder carcinoma with respect to basal versus luminal keratin expression
. Int J Mol Sci
. 2020
;21
(20
):7726
. 37.
Kim
B
, Jang
I
, Kim
K
, Jung
M
, Lee
C
, Park
JH
, et al. Comprehensive gene expression analyses of immunohistochemically defined subgroups of muscle-invasive urinary bladder urothelial carcinoma
. Int J Mol Sci
. 2021
;22
(2
):628
. 38.
Roux
A
, Loranger
A
, Lavoie
JN
, Marceau
N
. Keratin 8/18 regulation of insulin receptor signaling and trafficking in hepatocytes through a concerted phosphoinositide-dependent Akt and Rab5 modulation
. FASEB J
. 2017
;31
(8
):3555
–73
. 39.
Weng
YR
, Cui
Y
, Fang
JY
. Biological functions of cytokeratin 18 in cancer
. Mol Cancer Res
. 2012
;10
(4
):485
–93
. 40.
Choi
W
, Czerniak
B
, Ochoa
A
, Su
X
, Siefker-Radtke
A
, Dinney
C
, et al. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer
. Nat Rev Urol
. 2014
;11
(7
):400
–10
. 41.
Lindgren
D
, Liedberg
F
, Andersson
A
, Chebil
G
, Gudjonsson
S
, Borg
A
, et al. Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q
. Oncogene
. 2006
;25
(18
):2685
–96
. 42.
Sjodahl
G
, Lauss
M
, Lovgren
K
, Chebil
G
, Gudjonsson
S
, Veerla
S
, et al. A molecular taxonomy for urothelial carcinoma
. Clin Cancer Res
. 2012
;18
(12
):3377
–86
. 43.
Massari
F
, Ciccarese
C
, Santoni
M
, Iacovelli
R
, Mazzucchelli
R
, Piva
F
, et al. Metabolic phenotype of bladder cancer
. Cancer Treat Rev
. 2016
;45
:46
–57
. 44.
Jaiswal
PK
, Koul
S
, Palanisamy
N
, Koul
HK
. Eukaryotic translation initiation factor 4 gamma 1 (EIF4G1): a target for cancer therapeutic intervention
. Cancer Cell Int
. 2019
;19
:224
. 45.
Zhang
J
, Li
S
, Zhang
L
, Xu
J
, Song
M
, Shao
T
, et al. RBP EIF2S2 promotes tumorigenesis and progression by regulating MYC-mediated inhibition via FHIT-related enhancers
. Mol Ther
. 2020
;28
(4
):1105
–18
. 46.
Badura
M
, Braunstein
S
, Zavadil
J
, Schneider
RJ
. DNA damage and eIF4G1 in breast cancer cells reprogram translation for survival and DNA repair mRNAs
. Proc Natl Acad Sci U S A
. 2012
;109
(46
):18767
–72
. 47.
Jiang
B
, Li
EH
, Lu
YY
, Jiang
Q
, Cui
D
, Jing
YF
, et al. Inhibition of fatty-acid synthase suppresses P-AKT and induces apoptosis in bladder cancer
. Urology
. 2012
;80
(2
):484.e9–15
. 48.
Puts
GS
, Leonard
MK
, Pamidimukkala
NV
, Snyder
DE
, Kaetzel
DM
. Nuclear functions of NME proteins
. Lab Invest
. 2018
;98
(2
):211
–8
. 49.
Sharron Lin
X
, Hu
L
, Sandy
K
, Correll
M
, Quackenbush
J
, Wu
CL
, et al. Differentiating progressive from nonprogressive T1 bladder cancer by gene expression profiling: applying RNA-sequencing analysis on archived specimens
. Urol Oncol
. 2014
;32
(3
):327
–36
. 50.
Chu
X
, Guo
X
, Jiang
Y
, Yu
H
, Liu
L
, Shan
W
, et al. Genotranscriptomic meta-analysis of the CHD family chromatin remodelers in human cancers: initial evidence of an oncogenic role for CHD7
. Mol Oncol
. 2017
;11
(10
):1348
–60
. 51.
Alfert
A
, Moreno
N
, Kerl
K
. The BAF complex in development and disease
. Epigenetics Chromatin
. 2019
;12
(1
):19
. © 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.
